Analystreport

CymaBay Therapeutics Inc (NASDAQ: CBAY) was downgraded by analysts at Leerink Swann to a "hold" rating. They now have a $2.50 price target on the stock.

CymaBay Therapeutics Inc.  (CBAY) 
Last cymabay therapeutics inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cymabay.com